AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension

19th May 2026 Uncategorised 0

Baxdrostat delivers clinically meaningful blood pressure reductions in phase 3 BaxHTN trial

More: AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension
Source: News